T0	Interventions 10 22	enzalutamide
T1	Interventions 281 293	Enzalutamide
T2	Interventions 392 399	placebo
T3	Interventions 570 582	enzalutamide
T4	Interventions 782 805	enzalutamide 160 mg/day
T5	Interventions 814 824	or placebo
T6	Interventions 1652 1668	the enzalutamide
T7	Interventions 1700 1714	in the placebo
T8	Interventions 1828 1870	61 with enzalutamide compared with placebo
T9	Interventions 2005 2035	11·1-13·9) in the enzalutamide
T10	Interventions 2057 2069	(5·5-5·6) in
T11	Interventions 2182 2197	patients in the
T12	Interventions 2211 2221	group than
T13	Interventions 2566 2577	CI 5·6-5·7)
T14	Interventions 2612 2628	months (5·4-5·6)
T15	Interventions 2746 2758	enzalutamide
T16	Interventions 2924 2936	(32%) of 872
T17	Interventions 2980 2988	(37%) of
T18	Interventions 3101 3117	skeletal-related
T19	Interventions 3209 3225	(95% CI 23·9-not
T20	Interventions 3326 3352	improving overall survival